Impact of anesthesia and analgesia techniques on glioblastoma progression. A narrative review

Ann Privorotskiy, Shreyas P. Bhavsar, Frederick F. Lang, Jian Hu, and Juan P. Cata

Eastern Virginia Medical School, Norfolk, Virginia, USA (A.P.); Department of Anesthesiology and Perioperative Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA (S.P.B., J.P.C.); Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA (F.F.L.); Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA (S.P.B., J.H.)

Corresponding Author: Juan P. Cata, MD, Department of Anesthesiology and Perioperative Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Unit 409, Houston, TX 77005, USA (JCata@mdanderson.org).

Abstract
Glioblastoma (GBM) is an aggressive malignant CNS tumor with a median survival of 15 months after diagnosis. Standard therapy for GBM includes surgical resection, radiation, and temozolomide. Recently, anesthetics and analgesics have received attention for their potential involvement in mediating tumor growth. This narrative review investigated whether various members of the 2 aforementioned classes of drugs have a definitive impact on GBM progression by summarizing pertinent in vitro, in vivo, and clinical studies. Recent publications regarding general anesthetics have been inconsistent, showing that they can be pro-tumoral or antitumoral depending on the experimental context. The local anesthetic lidocaine has shown consistent antitumoral effects in vitro. Clinical studies looking at anesthetics have not concluded that their use improves patient outcomes. In vitro and in vivo studies looking at opioid involvement in GBM have demonstrated inconsistent findings regarding whether these drugs are pro-tumoral or antitumoral. Nonsteroidal anti-inflammatory drugs, and specifically COX-2 inhibitors, have shown inconsistent findings across multiple studies looking at whether they are beneficial in halting GBM progression. Until multiple repeatable studies show that anesthetics and analgesics can suppress GBM growth, there is no strong evidence to recommend changes in the anesthetic care of these patients.

Key Points
- General anesthetics and opioids do not impact survival after glioblastoma surgery.
- Regional anesthesia is not associated with improvement in survival after glioblastoma surgery.
- More studies are needed to elucidate if perioperative use of COX-2 inhibitors impact survival after glioblastoma surgery.

Gliomas are the most common type of malignancy in the CNS. These cancers arise from tumors in neural support cells such as astrocytes and oligodendrocytes. Glioblastoma (glioblastoma multiforme/GBM) is a type of very aggressive glioma and is associated with a poor prognosis. Current guidelines recommend gross total resection of the enhancing solid tumor followed by radiation and the oral alkylating chemotherapy agent temozolomide (TMZ). However, therapeutic strategies should be tailored based on age and functional status. Disease progression is the most common cause of death in patients with GBM; therefore, understanding the mechanisms and risk factors involved in tumor growth postoperatively has been the focus of extensive laboratory and clinical investigations.

In recent years, there has been a growing interest in determining the impact of anesthetics and analgesics in cancer progression. One theory is that short-term exposure to anesthetics, such as volatile anesthetics, could be associated with accelerated tumor growth. Similarly, it has been proposed that...
patients who are exposed to opioids in large quantities for days after surgery would suffer cancer progression more rapidly than those taking limited amounts of analgesics and for a shorter period. Lastly, researchers have speculated that regional anesthesia could have a beneficial impact on oncological outcomes since it could minimize opioid use, reduce the consumption of general anesthetics, and limit the stress response associated with surgery (Figure 1).7 

In this narrative review, we summarized the current laboratory and clinical evidence on the impact of different anesthetic and analgesic techniques on tumor progression.

**Glioblastoma: An Overview**

GBM is the most commonly occurring primary adult malignant CNS tumor in the United States, accounting for 48.3% of tumors in this category. With an incidence rate of 3.22 per 100,000 persons in the United States, this tumor is more common in males than females (1.6:1). Incidence rates are approximately twice as high in Whites than in Blacks. GBM is primarily diagnosed at a median age of 65 years old, and the incidence increases with age. GBM's 5-year relative survival rate is the lowest (6.8%) compared with the 5-year relative survival rate of all other malignant brain tumors. Thus, the prognosis is poor, with a median survival of 15 months after diagnosis is made.4

In 2016, the World Health Organization (WHO) reclassified CNS tumors based not only on their histologic features but also on their molecular parameters. This restructuring changed how clinicians diagnose and treat CNS tumors. GBM remained classified as a grade IV tumor, corresponding to the highest degree of malignancy, and was subclassified into the following 3 categories: isocitrate dehydrogenase (IDH)-wildtype, IDH-mutant, and not otherwise specified (NOS).4 IDH-wildtype is the most common variant of this disease, accounting for 90% of GBM cases. This type of GBM corresponds with primary/de novo GBM, occurs predominantly in patients over the age of 55 years, and has a wide anatomical distribution potential in the brain. IDH-mutant GBM accounts for the remaining 10% of all GBM cases and corresponds with secondary GBM. This type of malignant glioma is thought to have arisen from a low-grade astrocytoma, in contrast with primary GBM. IDH-mutant GBMs occur predominantly in a younger population (<55 years old), have a better prognosis than IDH-wildtype GBM, and are preferentially located in the frontal lobe. The diagnosis of NOS GBM should be reserved for scenarios in which IDH evaluation cannot be performed.9,10 The cIMPACT-NOW (the Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy) was established to rapidly integrate advances in brain tumor molecular pathogenesis into clinical practice. A recent recommendation from the CIMPACT-NOW is to designate diffuse, grade II or III, IDH-wildtype astrocytomas with molecular features of GBM directly as “Glioblastoma, IDH-wildtype.”11

**Genetic and Molecular Alterations**

Three signaling pathways are commonly deregulated in GBMs: loss of function of RB, loss of function of p53, and gain of function of RTK/RAS/P13K.12 Furthermore, certain genetic alterations have been found helpful in differentiating primary and secondary GBM tumors. Mutations commonly found in primary GBM include epithelial growth factor receptor (EGFR) overexpression and amplification, MDM2 amplification, deletion of p16, loss of heterozygosity (LOH) of chromosome 10q, and PTEN mutations. Mutations commonly found in secondary GBM include LOH of 19q, mutations in RB, CDKN2A amplification, and overexpression of platelet-derived growth factor (PDGF) PDGFA/PDGFRα.13

GBMs can also be classified based on transcriptome profiles into the following 4 subgroups: classical, mesenchymal, proneural, and neural. The classical subgroup exhibits loss of PTEN and amplification of CDKN2A and EGFR. The mesenchymal subgroup typically has mutations and/or loss of TP53, NF1, and CDKN2A. This variant is associated with a less favorable prognosis and is more frequent in older patients. The proneural transcriptome subgroup is characterized by mutations in CDK4, CDK6, PDGFRα, MET, and IDH1. In contrast to the mesenchymal subgroup, GBMs identified to be proneural are associated with younger patients and have a more favorable prognostic outcome. Additionally, proneural GBMs are associated with secondary GBMs. The neural subtype does not have a hallmark genetic profile but commonly has expression of neuron markers such as NEFL and GABRA1.14 Alterations in the above pathways allow GBMs to evade cell-cycle checkpoints and proliferate uncontrollably. Additionally, some mutations confer resistance to apoptotic stimuli allowing for enhanced tumor cell survival. Increased understanding of genomic contributions to GBM pathogenesis can aid in identifying novel therapeutic targets.15

The microenvironment surrounding GBM cells plays a crucial role in tumor development, progression, prognosis, and response to adjuvant therapies. In the tumor niche, GBM cells release attractant factors to recruit endothelial cells...
GAMs toward GBM cells and tumor reduction. Furthermore, PD-1 in vivo, they observed enhanced phagocytic function in anesthesia (TIVA). Volatile anesthetics such as isoflurane, volatile-based general anesthesia or total intravenous anesthesia. Surgical resection of GBM tumors can be performed under General Anesthetics

Impact of Anesthetics and Analgesics on GBM Progression

General Anesthetics

Surgical resection of GBM tumors can be performed under volatile-based general anesthesia or total intravenous anesthesia (TIVA). Volatile anesthetics such as sevoflurane, desflurane, and desflurane are administered as the base of inhalational anesthesia, while propofol is the most commonly used anesthetic for TIVA. Other intravenous agents such as dexmedetomidine are also frequently added as adjuvant anesthetics during craniotomies for tumors. This is done to provide analgesia and reduce anesthetic consumption. The term “combined general anesthesia” refers to the combination of volatile anesthesia and propofol anesthesia during surgery. The goal of using a combined general anesthesia technique is to reduce the adverse effects of either single agent (ie, volatile anesthesia–induced nausea and vomiting).

Experimental studies investigated whether general volatile or intravenous anesthetics can either potentiate or inhibit tumor malignancy factors such as cell migration, invasion, and proliferation (Table 1). One proposed mechanism by which volatile anesthetics impact cancer outcomes is by mediating gene expression in tumor cells. For instance, short-term exposure of glioma cells to isoflurane and desflurane modulated gene expression in a time-dependent manner. Babateen et al. reported that the human GBM cell line U3047MG abundantly expressed functional GABA A subunit receptors, and these receptors can be modulated by classic GABA-targeting anesthetics. Thus, different groups of researchers have investigated the impact of GABA-targeting anesthetics on GBM cell behaviors. Lai et al. found that 4% sevoflurane promotes pro-tumoral characteristics in human GBM cell lines U251, A172, and U87. Interestingly, a different study showed contrary findings; U251 and U87 cells exhibited decreased proliferation,

| Author/Year | Study Design | Pertinent Findings |
|-------------|--------------|---------------------|
| Lai (2019)  | In vitro and in vivo (mice) Human GBM U251, U87 and A172 cells Cultured for 4 h 1%-4% sevoflurane | Sevoflurane exhibits pro-tumoral properties in GBM cells at least in part by upregulation of CD44. |
| Gao (2019)  | In vitro Human GBM U251 and U87 cells. Cultured for 4 h with 4% sevoflurane | Sevoflurane exhibits antitumoral properties in glioma cells at least in part by modulation of the miRNA-124-3p/ROCK1 pathway. |
| Li (2020)   | In vitro U251 and A172 cells 5 µg/mL or 10 µg/mL of propofol for 24 h | Propofol exhibits antitumoral properties in glioma cells at least in part by modulation of the miR-410-3p/TGFBR2 pathway. |
| Cata (2017) | Clinical retrospective study (n = 261 desflurane, n=117 isoflurane) | In the context of GBM surgery, neither isoflurane nor desflurane impact PFS and/or OS in patients. Median PFS and OS times were 8.84 (7.92–10.28) and 19 (17.31–22.93) months, respectively. At 5 years, the progression and overall mortality rate were 93% and 85%. Exposure to isoflurane exposure was longer than desflurane (P<.002). |
| Grau (2020) | Clinical retrospective study (n = 158) | The choice of inhaled anesthetics vs TIVA in surgical resection of GBM does not impact patient survival. No significant difference in recurrence-free survival (volatiles: 8.0 vs TIVA: 8.4 months; P = .54) or OS (propofol: 17.4 vs volatiles: 16.9 months; P = .85). |
| Dong (2019) | Clinical retrospective study (n = 154 propofol, n = 140 sevoflurane) | The choice of propofol vs sevoflurane in surgical resection of GBM does not impact patient survival. Median PFS was 10 months propofol vs 11 months sevoflurane. Median OS was 18 months propofol vs 18 months sevoflurane. |

GBM, glioblastoma; miRNA-124-3p, microRNA-124-3p; miR-410-3p, microRNA-410-3p; OS, overall survival; PFS, progression-free survival; ROCK1, Rho-associated coiled-coil containing protein kinase 1; TGFBR2, transforming growth factor-β receptor type 2; TIVA, total intravenous anesthesia.
invasion, and migration abilities after treatment with the same concentration of sevoflurane as previously described. The proposed mechanism behind these findings was via upregulation of microRNA(miR)-124-3p.27 The inconsistencies in these studies can be explained by different experimental conditions. The involvement of miRNAs in anesthetic antitumor effects was additionally observed in GBM cells treated with propofol. Remarkably, when glioma cells were treated with propofol, they showed inhibited cell proliferation, migration, and invasion, thought to be mediated at least in part via upregulation of miR-410-3p.27

As previously mentioned, gain of function of the RTK/RAS/PI3K pathway is critical in GBM tumorigenesis.12 Volatile anesthetics are known modulators of RAS/PI3K signaling in different cancer cell lines including hepatocarcinoma, in which they have shown to promote apoptosis and inhibit migration.28 Volatile anesthetics can also regulate cell division by acting on p53 signaling. This was suggested by Ni et al. who reported that isoflurane inhibited the repair of DNA damage in human neuroglioma cells via the p53 signaling pathway.29 However, it is unknown whether the effects of volatile anesthetics on the RAS/PI3K and p53 pathways affect the behavior of GBM cells.

Volatile anesthetics and propofol appear to have opposite effects on the innate immune system. While volatile anesthetics inhibit the function of NK cells, propofol has some stimulatory effects on these cells.30 A decreased expression of the adhesion molecule leukocyte-associated antigen-1 has been proposed as one of the mechanisms by which isoflurane and sevoflurane suppress the function of NK cells.31 In contrast, propofol can stimulate the function of NK cells by increasing the expression of granzyme B and IFN-γ activating surface receptors (CD16, NKp30, NKp44, and NKG2D), and inhibiting prostaglandin E2 formation.32–34 It is worth considering that the immunomodulatory effects of general anesthetics have been evaluated in vitro in NK cells; therefore, it remains to be determined whether the function of NK cells and lymphocytes is altered in the GBM microenvironment in vivo.

When considering the impact of anesthetics on GBM progression, it is important to understand that the duration of exposure to these drugs is short (2–6 h) and dependent on the duration of surgery.27 As expected, longer operations are required for larger and/or more complex tumors; thus, impact of any anesthetic on tumor progression is significantly confounded by time of surgery. Also, the dosage of the anesthetic used during surgery is confounded by duration of surgery. The cumulative dose of agents like propofol is higher after longer surgeries. Our group reported that neither isoflurane nor desflurane had any impact on the progression-free survival (PFS) and overall survival (OS) rates in patients who had exposure to either of these anesthetics during craniotomy for GBM.22 More recently, 2 observational studies investigated the association between the use of TIVA versus volatile-based general anesthesia during GBM resection. The studies included 158 and 294 patients and concluded that the TIVA was not associated with any improvement in survival.35,36 These studies suggest that the method of delivering general anesthetics does not influence GBM progression after surgery.

### Local Anesthetics

Regional anesthesia is currently recommended for adequate perioperative pain control after craniotomy.37 It has been speculated that regional anesthesia could reduce cancer progression by various mechanisms acting synergistically, including via a reduction in opioid and general anesthetic use, modulation of the stress response, and the direct effect of local anesthetics on the tumor microenvironment after their systemic absorption.38 Based on

#### Table 2. Summary of Preclinical and Clinical Studies Investigating the Effects of Lidocaine and Regional Anesthesia on GBM Biology and Patients’ Survival

| Author/Year | Study Design | Pertinent Findings |
|-------------|--------------|-------------------|
| Izdebska (2018) | In vitro C6 rat glioma cells Treated for 24 h with 0.25, 0.5, 1, 5, 10, 15, and 30 mM of lidocaine | Lidocaine exhibits antitumoral effects in rat glioma cells at least in part by cytoprotective autophagy. |
| Leng (2017) | In vitro C6 rat glioma cells Treated with 1 and 3 mM lidocaine | Lidocaine exhibits antitumoral effects at least in part by inhibition of transient receptor potential melastatin 7 channels. |
| Lu (2016) | In vitro U87 cells Treated with 1, 5, 10, 20, and 40 mmol/L of lidocaine, | Lidocaine exhibits antitumoral effects at least in part by induction of apoptosis secondary to increased intracellular calcium ion concentration, and mitochondrial membrane potential. |
| Zheng (2017) | Clinical retrospective study (n = 119) | Use of scalp block in GBM patients undergoing tumor resection is associated with reduced inflammation and improved survival. Median PFS was 16.7 months in patients who had scalp block vs 6.5 months in those who did not (P < .001). |
| Cata (2018) | Clinical retrospective study (n = 808) | Use of scalp block in brain tumor resection is not associated with improved patient survival. Median PFS time was 769 months; 5-year PFS rate was 8%. Median OS time was 16.82 months; 5-year OS rate was 17%. |

GBM, glioblastoma; OS, overall survival; PFS, progression-free survival.
these premises, the effects of local anesthetics in glioma cells have been investigated in vitro (Table 2). Overall, lidocaine has shown to induce apoptosis and autophagy in rat C6 glioma cells. Several mechanisms were proposed, including a blockade of current in transient receptor potential melastatin 7 channels with concentrations of lidocaine ranging from 1 to 3 mM and induction of alteration in the cellular cytoskeleton. In U87-MG glioma cells, lidocaine triggered dose-dependent apoptosis by increasing intracellular calcium concentrations. It is unknown how the in vitro findings translate to in vivo. To the best of our knowledge, the effects of lidocaine or any other local anesthetics have not been tested in GBM animal models.

Local anesthetics have shown antiangiogenic and immunomodulatory effects. Lidocaine administered systemically (30 mg/kg) to mice with melanoma decreased tumor growth by inducing apoptosis in endothelial cells. Furthermore, lidocaine in clinically relevant concentrations enhanced the function of NK cells and inhibited the production of IL-6, tumor necrosis factor (TNF-α), and IL-12 from activated dendritic cells. In humans, the use of scalp blocks for GBM surgery was associated with a lower neutrophil to lymphocyte ratio, suggesting a modulatory effect of regional anesthesia on inflammation.

While the effects of local anesthetics have not been evaluated in clinical trials, our group investigated whether the use of regional anesthesia has any effects on PFS and OS after surgery. Briefly, we were unable to demonstrate a beneficial association between the use of scalp blocks and progression-free or OS in a cohort of 534 patients. It remains unknown whether the intravenous infusion of lidocaine would have any impact on survival after GBM surgery.

Opioids

Modulation via μ-opioid receptors has been theorized as adjuvant therapy in overcoming the enhanced chemo- and radioresistance in GBMs. Methadone has received particular attention regarding its potential role in GBM progression. Friesen et al. demonstrated that methadone reduced tumor cell malignancy by enhancing apoptosis and increasing sensitivity to treatment with doxorubicin in 2 GBM cell lines. Additionally, the study reported tumor growth inhibition in vivo in mice treated with methadone. Unfortunately, subsequent investigations showed that the antitumor effects of methadone are only exhibited at high concentrations that would not be clinically feasible in patients. One study demonstrated that at elevated concentrations of this opioid, GBM cells exhibit increased apoptosis and reduced cell viability. However, when cells were treated with clinically relevant concentrations, methadone did not promote any antitumorigenic effects, and one cell line even showed higher proliferation after treatment compared to controls. Similarly, Opperman et al. reported reduced GBM cell viability only when treated with concentrations of methadone that have previously been reported to be toxic in patients. Additionally, the study showed that methadone did not improve tumor cell response when combined with the standard therapies of TMZ and/or radiation.

In addition to methadone, enkephalin has also been investigated for potential roles in mitigating GBM. Biphalin, an enkephalin analog, has been of interest in recent years due to its less addictive nature and high analgesic potency as compared to morphine. Biphalin treatment resulted in antitumorigenic effects including reduced proliferation rates and colony formation in human GBM cells. Interestingly, morphine displayed the opposite effect and stimulated tumor cell proliferation. In a study by Heiss et al., activation of the μ-opioid receptor by enkephalin and etorphine (a synthetic analog of morphine) promoted tumor cell survival by inhibition of apoptosis in neuroblastoma-x glioma hybrid cells. These effects were believed to be mediated by activation of the Akt pathway. Though a different cancer cell line was used in the study investigating the effects of biphalin, the tumor cytoprotective effects seen in the neuroblastoma-x glioma hybrid cells after treatment with enkephalin and etorphine raise concern regarding the safety profile of similar opioids in the context of GBM.

The results of experimental studies demonstrate that opioids can impair mechanisms of immune surveillance and modulate inflammation. Forget et al. reported that the systemic administration of fentanyl (40 μg/kg) to rats undergoing surgery promoted metastasis. Similarly, when patients were treated with a large dose of fentanyl (75 μg/kg) during surgery, they had a prolonged (48 h) suppression of NK cell cytotoxicity compared to those receiving a low dose (1 μg/kg). Opioids can directly activate toll-like receptor-4, which results in the release and expression of inflammatory mediators including IL-1, IL-6, TNF-α, and NF-κB metalloproteinase-9. Toll-like receptors participate in tumor-related inflammation by promoting migration of macrophages from the circulation into the tumor microenvironment and facilitating M2 polarization. Recently, Gjorgjievski et al. reported that the M2-like phenotype was associated with poor prognosis in patients with GBM.

To the best of our knowledge, there have not been any published clinical trials or observational studies investigating the role of opioids on GBM tumor progression. While it appears that methadone does not have antitumoral capabilities at clinically nontoxic concentrations, biphalin and enkephalin should be further explored as potential GBM mediating treatments due to inconsistent findings in vitro. Further in vitro and in vivo animal testing should be performed to definitively rule out any possibility of pro-tumoral contributions before considering the introduction of these drugs into clinical settings.

COX-2 Inhibitors

Among the many different signaling molecules involved in gliomagenesis, the cyclooxygenase-2 (COX-2) enzyme has been implicated as a main driver of malignancy. Elevated levels of COX-2 are associated with more aggressive types of tumors and worse prognoses. A study by Xu et al. demonstrated that COX-2 increases the malignancy of GBM cells via increased cell growth, invasion potential, and vascularization. This study found that the mechanism by which COX-2 increases malignancy is via downstream enhanced expression of Id1, a member of the helix-loop-helix family of transcriptional repressors. As given in Table 4, several other studies have proposed additional mechanisms and pathways by which COX-2 is involved in tumorigenesis, and have tested these effects using selective COX-2 inhibitors.
In addition to COX-2 inhibitors, other nonsteroidal anti-inflammatory drugs (NSAIDs) (ie, diclofenac, ibuprofen, and meloxicam) have also been studied as a potential therapy for GBM (Table 3). These NSAIDs have been shown to exhibit their effects via COX-dependent or COX-independent mechanisms. Using an in vivo rat brain model, Oksuz et al. reported that acetaminophen and indomethacin can reduce GBM growth at least in part by inhibition of COX-3. To maximize targeted delivery of this drug class, nanoparticles have been developed and assessed for safety and efficacy. Indomethacin- and ketoprofen-loaded nanocapsules have both been shown to reduce tumor size in a rat glioma model. The common NSAID ibuprofen has been studied in the redesigned form of phospho-glycerol-ibuprofen-amide (PGIA). PGIA formulated in a rat glioma model. The common NSAID ibuprofen has been shown promise in this particular subset of patients, the combination of this vitamin A analog with celecoxib was tested. Results showed that there was no improved efficacy of combination 13-cRA and celecoxib in the treatment of recurrent GBM, compared to 13-cRA alone. To better understand the pharmacokinetics of COX-2 inhibitors in combination with hepatic enzyme-inducing antiseizure drugs (EIASDs), Grossman et al. conducted a study to determine the effects of phenytoin on celecoxib in patients undergoing radiation therapy for GBM. Results showed that there was no clinically significant pharmacologic interaction between these 2 drugs, and that is safe to administer them in combination.

**Table 3. Summary of Preclinical and Clinical Studies Investigating the Effects of COX-2 Inhibitor and NSAIDs on GBM Biology**

| Author/Year   | Study Design | Pertinent Findings                                                                 |
|---------------|--------------|------------------------------------------------------------------------------------|
| Friesen (2014)| In vitro and in vivo Human GBM A172 and U118MG cells in vitro, U87MG cell line used in vivo Methadone: 10, 3, 1, μg/mL Doxorubicin: 0.1, 0.3 μg/mL | Methadone exhibits antitumoral effects by increasing the sensitivity of GBM cells to doxorubicin, at least in part by downregulation of cAMP. |
| Brawanski (2018)| In vitro U82 and U251 cells D,L-methadone was applied at concentrations of 0.3, 1, 15, 30, and 45 μg/mL. | Methadone exhibits antitumoral effects in GBM cells only at clinically unattainable concentrations. |
| Oppermann (2019)| In vitro Primary GBM and fibroblast cell cultures from 7 patients. Treated with 200 μM TMZ and/or D,L-methadone at 0, 1 nM, 10 nM, 0.1 μM, 1 μM, 5 μM, 10 μM, and 30 μM for 72 h. After that, cells were X-irradiated at a total dose of 4 Gy. | Methadone exhibits antitumoral effects in GBM cells only at clinically unattainable concentrations. Methadone does not interact with standard therapies such as TMZ and X-irradiation. |
| Lazarczyk (2019)| In vitro Human glioma T98G cells were treated with opioid peptide biphalin hydrochloride concentrations ranging from 50 nM to 40 μM. | Biphalin may be a better alternative to morphine due to its comparatively improved ability to inhibit human GBM cell growth. |
| Heiss (2009)| In vitro Neuroblastoma x glioma (NG108-15) hybrid cells were treated for 5 min with increasing concentrations of enkephalin and etorphine from 10 nM to 1 μM. | Delta-opioid receptor agonists exhibit pro-tumoral properties mediated by activation of the RTK/Pi3K/Akt signaling pathway in neuroblastoma x glioma hybrid cells. |

Inhibitors such as celecoxib and parecoxib. Kang et al. demonstrated that when cells were treated with celecoxib, they were more susceptible to p53-induced damage via cell-cycle arrest and autophagy.

It has been shown that COX-2 inhibition via administration of parecoxib can sensitize cells to immunotherapy. These effects were seen in vitro in rat glioma cells, and in vivo in rats that showed increased survival rates after treatment with a combination of parecoxib and immunotherapy, compared with those who received immunotherapy alone. Similarly, it has been reported that treatment with celecoxib can enhance the radiosensitivity of GBM cells, at least in part by increasing stress on the endoplasmic reticulum. Additionally, celecoxib has been shown to increase apoptosis and reduce self-renewal capacity in glioma cancer stem cells.

Other studies have proposed that celecoxib can suppress tumor progression via pathways that are independent of COX, including the deregulation of the Wnt/β-catenin/Tcf and NF-κB pathways.

Due to their encouraging preclinical results indicating efficacy against GBMs, clinical studies have been done to examine how COX-2 inhibitors impact tumor progression. Several studies have been conducted to evaluate if TMZ in combination with COX-2 inhibitors can improve patient outcomes. A phase II factorial design showed that TMZ in combination with the cytostatic drugs thalidomide, isotretinoin, and/or celecoxib did not enhance treatment efficacy compared to TMZ alone.

Similarly, another phase II study looking at TMZ, thalidomide, and celecoxib combination therapy in newly diagnosed adult GBM patients found that while this triple combination was well tolerated, it did not significantly improve PFS. Levin et al. conducted a phase II clinical trial to determine if celecoxib improves outcomes in patients with recurrent GBM. Because 13-cis-retinoic acid (13-cRA) has previously shown promise in this particular subset of patients, the combination of this vitamin A analog with celecoxib was tested. Results showed that there was no improved efficacy of combination 13-cRA and celecoxib in the treatment of recurrent GBM, compared to 13-cRA alone.

NSAIDs and Other Analgesics

In addition to COX-2 inhibitors, other nonsteroidal anti-inflammatory drugs (NSAIDs) (ie, diclofenac, ibuprofen, and meloxicam) have also been studied as a potential therapy for GBM.
### Table 4. Summary of Preclinical and Clinical Studies Investigating the Effects of COX-2 Inhibitors and NSAIDs on GBM Biology and Patients’ Survival

| Author/Year     | Study Design                                                                 | Pertinent Findings                                                                 |
|-----------------|------------------------------------------------------------------------------|-----------------------------------------------------------------------------------|
| Kang (2009)     | In vitro Human GBM cells U87MG, U373MG, LN229, and U87MG-E6. Cells were treated with celecoxib at 8 and 30 μM for 5, 18, and 72 h. | Antitumoral properties of celecoxib are mediated at least in part by p53 modulation in human GBM cells. |
| Eberstal (2012) | In vitro and in vivo. N32 rat glioma cell line. Parecoxib was administered to rats at 5 mg/kg/day. | Parecoxib potentiates immunotherapy in GBM.                                         |
| Suzuki (2013)   | In vitro. Two human cell lines (U87MG and U251MG) and one mouse cell line (GL261) were treated with celecoxib at 10–70 μM for 48 h. | Celecoxib potentiates radiotherapy in GBM, at least in part by increasing stress on the ER. |
| Sharma (2011)   | In vitro. Cancer stem-like cells from U87MG cells treated with 10 μM celecoxib. | Celecoxib exhibits antitumoral effects in GBM cancer stem cells independently of IL-1β. |
| Sareddy (2013)  | In vitro. U87 and U251 cells were treated with 50–200 μM diclofenac or 20–80 μM celecoxib for 24 h. | Celecoxib and diclofenac exhibit antitumoral effects at least in part by inhibition of the Wnt/B-catenin/Tcf pathway signaling pathway. |
| Sareddy (2011)  | In vitro. U373, GOG-C-CM, T98G, and A127 cell lines were treated with 20, 40, 60, and 80 μmol/l for 12, 24, and 36 h. | Celecoxib exhibits antitumoral effects at least in part by inhibition of the NF-κB signaling pathway. |
| Oksuz (2015)    | In vivo (mice). C6 cell tumor bearing rats were treated with either acetaminophen 150 mg/kg, metamizole 150 mg/kg, or indomethacin 10 mg/kg for 5 consecutive days. | Acetaminophen and indomethacin exhibit antitumoral effects at least in part by inhibition of COX-3. |
| Bernardi (2009) | In vivo (mice) C6 glioma cells were injected into male rats and were either untreated, treated with drug-unloaded nanoparticles, treated with 1 mg/kg/day of indomethacin in solution, or treated with 1 mg/kg/day of indomethacin-loaded nanoparticles for 10 consecutive days. | Indomethacin-loaded nanocapsules exhibit greater antitumoral effects than indomethacin in solution, seen in rat GBM model. |
| Da Silveira (2013) | In vitro and in vivo (rats) Rat (C6) and human (U118MG, U251MG) GBM cell lines were treated with 1, 10, 50, and 100 μM ketoprofen or ketoprofen-loaded nanoparticles for 48 or 72 h. Rats implanted with C6 glioma cells received treatment with 3 mg/kg/day of ketoprofen or 3 mg/kg/day of ketoprofen-loaded nanoparticles for 15 consecutive days. | Ketoprofen-loaded nanoparticles exhibit antitumoral effects in a panel of glioma cell lines and glioma-bearing rats. |
| Bartels (2016)  | In vitro and in vivo (mice) U87-MG, LN-18, LN-229, and U118-MG cells were treated with 0.5×, 0.75×, or 1× IC50 for 24 h. Mice were injected with U118-MG or U87-MG cells and treated with 20 mg/kg PGIA given 1×/day, 5 day/week for 12 days. | PGI2 formulated in nanoparticles is a promising therapy for GBM, and can exhibit more potent antitumoral effects than traditional ibuprofen. |
| Wakimoto (2008) | In vitro. T98G, U118, U343, and U373 cells were treated with 100 μmol/L of diclofenac or 10 μmol/L of meloxicam for 48 h. | NSAIDs (diclofenac and meloxicam) exhibit antitumoral effects at least in part by upregulation of 15-PGDH. |
| Najbauer (2015) | In vitro. U87MG and A172 cells were treated with diclofenac (0.05–0.2 mM), ibuprofen (0.5–2 mM), or ASA (0.05–0.2 mM) for 24 h. | Ibuprofen and diclofenac both exhibit antitumoral effects, but achieve this via different mechanisms. |
| Pantovic (2017) | In vitro. U251 MG cells were treated for 24 h with 0–1 mM indomethacin for 12, 24, and 48 h. | Indomethacin exhibits antitumoral effects at least in part by mediation of the AMPK/mTORC1 pathway. |
| Foulkes (2012)  | In vitro. SH-SY5Y neuroblastoma cells were treated with 1 or 2 mM AAP for 24, 48, and 72 h. | Acetaminophen exhibits antitumoral properties in neuroblastoma cells at least in part by reactive oxygen species and IL-1β, along with NF-xB and p65 upregulation. |
| Penas-Prado (2015) | Randomized phase 2 adjuvant factorial clinical trial (n = 155) | Addition of thalidomide, isotretinoin, and/or celecoxib to TMZ did not improve treatment efficacy in GBM. Improved OS S was seen for triplet (20.1 months) vs doublet (17.0 months) regimens (P = .15). Compared with TMZ, the TMZ + isotretinoin doublet had worse PFS (10.5 vs 6.5 months, P = .043) and OS (21.2 vs 11.7 months, P = .037). |
inhibition of GBM growth in both in vivo and in vitro mice xenograft models compared to regular ibuprofen. The antitumoral properties of diclofenac and meloxicam are partly regulated via increased expression of 15-PGDH and the cell-cycle inhibitor p21. Diclofenac was also described to cause tumor inhibition by suppression of STAT-3 signaling and downstream glycolysis mediation. The same study reported that ibuprofen can reduce glioma cell proliferation and migration ability to a greater extent than diclofenac, and that these mechanisms are COX-independent as well. Indomethacin has been shown to induce cell-cycle arrest, oxidative stress, mitochondrial depolarization, and apoptosis in human glioma cells. These effects were believed to be mediated by AMPK/mTORC1, another COX-independent pathway. The common analgesic acetaminophen has been shown to decrease neuroblastoma tumor cell viability by increased production of reactive oxygen species and IL-1β, accompanied by activation of p65 and NF-xB. In vitro analysis of GBM cells with the same drug showed that this tumor cell line was more resistant to acetaminophen-induced cell damage.

Similar to COX-2 inhibitors, clinical studies have looked at NSAID efficacy in GBM as well. The results of these all-encompassing NSAID studies have shown inconsistent findings. A case–control study by Scheurer et al. found that regular use of NSAIDs was associated with a preventive effect against GBM, primarily in those with no history of asthma or allergies. Similarly, another case–control study found associations that suggest regular NSAID use, particularly aspirin, may reduce the incidence of glioma.

On the other hand, a large prospective cohort study by Daugherty et al. found no evidence that regular NSAID use reduces the risk of GBM. To date, there are no studies that have investigated the perioperative use of NSAIDs or COX-2 inhibitors on glioma progression, perhaps due to the potential associated risk of perioperative bleeding. Other concerns associated with the prolonged administration of NSAIDs and COX-2 inhibitors include gastrointestinal, renal, neurological, and cardiac toxicities. In July 2015, the FDA released a warning on the chronic administration of non-aspirin NSAIDs increasing the risk for strokes and heart attacks (www.fda.gov/Drugs/DrugSafety/ucm451800.htm). Celecoxib (Celebrex) is currently the only selective COX-2 inhibitor in the United States, with an FDA-mandated black box warning for its potential gastrointestinal and cardiovascular adverse events.

### Conclusion and Future Directions

GBMs are highly aggressive tumors with poor prognosis. Surgery is recommended to attain local control of the disease. Currently, there is no strong evidence to recommend changes in the anesthetic technique or analgesic care of patients undergoing GBM resection. Scalp block or wound infiltration techniques should be performed when possible to facilitate emergence from anesthesia, provide adequate perioperative pain relief, and reduce opioid use. Opioids should be given judiciously to treat severe perioperative pain. There is no convincing evidence that COX-2 inhibitors and NSAIDs should be pursued further for the treatment of
GBM. Anesthesiologists should focus on the impact of anesthetics and analgesics during GBM surgery in perioperative outcomes such as pain, quality of life, rehabilitation, time to discharge, and other related metrics.

In conclusion, GBM growth and progression is a complex process. It remains poorly understood whether the cellular events triggered during surgery and anesthesia in cancer cells are diminished or amplified by adjuvant therapies, which can confound the effect of anesthetics on survival outcomes. While the in vitro effects of anesthetics on cancer cells are diminished or amplified by adjuvant therapies, which can confound the effect of anesthetics on survival outcomes.

Keywords
anesthetic | analgesic | glioblastoma | progression

Funding
No funding was received for this study.

Conflict of interest statement. The authors do not have any conflict of interest related to this research.

References

1. Alcantara Llaguno SR, Parada LF. Cell of origin of glioma: biological and clinical implications. Br J Cancer. 2016;115(12):1445–1450.
2. Davis ME. Glioblastoma: overview of disease and treatment. Clin J Oncol Nurs. 2016;20(Suppl)S2–S8.
3. van den Bent MJ, Aldape KD, Reardon DA, et al. Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society for Neuro-Oncology (EANO) consensus review on current management and future directions. Neuro Oncol. 2020;22(8):1073–1113.
4. Stupp R, Mason WP, van den Bent MJ, et al.; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987–996.
5. Sesslser DI, Riedel B. Anesthesia and cancer recurrence: context for divergent study outcomes. Anesthesiology. 2019;130(1):5–9.
6. Novy DM, Nelson DV, Koyyalagunta D, Cata JP, Gupta P, Gupta K. Pain, opioid therapy, and survival: a needed discussion. Pain. 2019;161(3):496–501.
7. Cata JP, Gottumukkala V, Sesslser DI. How regional analgesia might reduce postoperative cancer recurrence. Eur J Pain Suppl. 2011; 5(S2):345–355.
8. Ostrom GT, Goff G, Gittleman H, et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2012–2016. Neuro Oncol. 2019; 21(suppl 5):v1–v100.
9. Louis DN, Perry A, Reifenberger G, et al. The 2016 world health organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016;131(6):803–820.
10. Ohgaki H, Kleihues P. The definition of primary and secondary glioblastoma. Clin Cancer Res. 2013;19(4):764–772.
11. Brat DJ, Aldape K, Colman H, et al. cIMPACT-NOW update 3: recommended diagnostic criteria for “Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV”. Acta Neuropathol. 2018;136(5):805–810.
12. Network CGAR. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008; 455(7216):1061–1068.
13. Hanif F, Muzaffer K, Perveen K, Malhi SM, Simjee ShU. Glioblastoma multiforme: a review of its epidemiology and pathogenesis through clinical presentation and treatment. Asian Pac J Cancer Prev. 2017;18(1):3–9.
14. Verhaak RG, Hoadley KA, Purdom E, et al.; Cancer Genome Atlas Research Network. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRα, IDH1, EGFR, and NF1. Cancer Cell. 2010;17(1):98–110.
15. Olar A, Aldape KD. Using the molecular classification of glioblastoma to inform personalized treatment. J Pathol. 2014;232(2):165–177.
16. Fu W, Wang W, Li H, et al. Single-cell atlas reveals complexity of the immunosuppressive microenvironment of initial and recurrent glioblastoma. Front Immunol. 2020;11:835.
17. Lee-Chang C, Rashidi A, Miska J, et al. Myeloid-derived suppressive cells promote b cell-mediated immunosuppression via transfer of PD-L1 in glioblastoma. Cancer Immunol Res. 2019;7(12):1929–1943.
18. Goswami S, Walle T, Cornish AE, et al. Immune profiling of human tumors identifies CD73 as a combinatorial target in glioblastoma. Nat Med. 2020;26(1):39–46.
19. Gordon SR, Mauto RL, Dulken BW, et al. PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity. Nature. 2017;545(7655):495–499.
20. Shu C, Li Q. Current advances in PD-1/PD-L1 axis-related tumour-infiltrating immune cells and therapeutic regimens in glioblastoma. Crit Rev Oncol Hematol. 2020;151:102965.
21. Wang L, Shen J, Ge L, et al. Dexametadomine for craniotomy under potentiate GABA-evoked GABAA currents in a cell line derived from human glioblastoma. Cancer Res. 2017;77(12):3583–3591.
22. Cata JP, Hagan KB, Bhavsar SD, et al. The use of isoflurane and desflurane as inhalational agents for glioblastoma surgery. A survival analysis. J Clin Neurosci. 2017;35:82–87.
23. Huittink JM, Heimerikks M, Nieuwland M, et al. Volatile anesthetics modulate gene expression in breast and brain tumor cells. Anesth Analg. 2010;111(6):1411–1415.
24. Babateen O, Jin Z, Bhandage A, et al. Etoposide and propofol potentiate GABA-evoked GABAA currents in a cell line derived from human glioblastoma. Eur J Pharmacol. 2015;748:101–107.
25. Lai RC, Shan WR, Zhou D, et al. Sevoflurane promotes migration, invasion, and colony-forming ability of human glioblastoma cells possibly via increasing the expression of cell surface protein 44. Acta Pharmacol Sin. 2019;40(11):1424–1435.
26. Gao C, Shen J, Meng ZX, He XF. Sevoflurane inhibits glioma cells proliferation and metastasis through miRNA-124-3p/ROCK1 Axis. Pathol Oncol Res. 2020;26(2):947–954.
27. Li F, Li F, Chen W. Propofol inhibits cell proliferation, migration, and invasion via mir-410-3p/transforming growth factor-β receptor type 2 (TGFBR2) axis in glioma. Med Sci Monit. 2020;26:e919523.
28. Hu J, Hu J, Jiao H, Li Q. Anesthetic effects of isoflurane and the molecular mechanism underlying isoflurane-inhibited aggressiveness of hepatic carcinoma. Mol Med Rep. 2018;18(1):184–192.
29. Ni C, Li C, Dong Y, Guo X, Zhang Y, Xie Z. Anesthetic isoflurane induces DNA damage through oxidative stress and p53 pathway. Mol Neurobiol. 2017;54(5):3531–3605.

30. Melamed R, Bar-Yosef S, Shakhar G, Shakhar K, Ben-Eliyahu S. Suppression of natural killer cell activity and promotion of tumor metastasis by ketamine, thiopental, and halothane, but not by propofol: mediating mechanisms and prophylactic measures. Anesth Analg. 2003;97(5):1331–1339.

31. Tázawa K, Koutsogiannaki S, Chamberlain M, Yuki K. The effect of different anesthetics on tumor cytotoxicity by natural killer cells. Toxicol Lett. 2017;266:23–31.

32. Liu D, Sun X, Du Y, Kong M. Propofol promotes activity and tumor-killing ability of natural killer cells in peripheral blood of patients with colon Cancer. Med Sci Monit. 2018;24:6119–6128.

33. Zhou M, Dai J, Zhou Y, et al. Propofol improves the function of natural killer cells from the peripheral blood of patients with esophageal squamous cell carcinoma. Exp Ther Med. 2018;16(1):83–92.

34. Inada T, Kubo K, Shingu K. Promotion of interferon-γ production by natural killer cells via suppression of murine peritoneal macrophage prostaglandin E2 production using intravenous anesthetic propofol. Int Immunopharmacol. 2010;10(10):1200–1208.

35. Grau SJ, Löth M, Taurisano V, et al. The choice of anesthesia for glioblastoma surgery does not impact the time to recurrence. Sci Rep. 2020;10(1):5556.

36. Dong J, Zeng M, Ji N, et al. Impact of anesthesia on long-term outcomes in patients with supratentorial high-grade glioma undergoing tumor resection. J Neurosurg Anesthesiol. 2019;32(3):227–233.

37. Guilfoyle MR, Helmy A, Duane D, Hutchinson PJ. Regional scalp block for postcraniotomy analgesia: a systematic review and meta-analysis. Anesth Analg. 2013;116(5):1093–1102.

38. Cota JP. Outcomes of regional anesthesia in cancer patients. Curr Opin Anaesthesiol. 2018;31(5):593–600.

39. Izdebska M, Halas-Wiśniowska M, Zielińska W, Klimaszewska-Wiśniowska A, Grzanka D, Gagat M. Lidocaine induces protective autophagy in rat C6 glioma cell line. Int J Oncol. 2019;54(3):1089–1111.

40. Leng T, Lin S, Xiong Z, Lin J. Lidocaine suppresses glioma cell proliferation by inhibiting TRPM7 channels. Int J Physiol Pathophysiol Pharmacol. 2017;9(2):8–15.

41. Lu J, Ju YT, Li C, Hua FZ, Xu GH, Hu YH. Effect of TRPV1 combined with lidocaine on cell state and apoptosis of U87-MG glioma cell lines. Asian Pac J Trop Med. 2016;9(3):288–292.

42. Gao J, Hu H, Wang X. Clinically relevant concentrations of lidocaine inhibit tumor angiogenesis through suppressing VEGF/VEGFR2 signaling. Cancer Chemother Pharmacol. 2019;83(6):1007–1015.

43. Yardeni IZ, Beilin B, Mayburd E, Levinson Y, Bessler H. The effect of perioperative intravenous lidocaine on postoperative pain and immune function. Anesth Analg. 2009;109(5):1464–1469.

44. Shin E-C, Jeon Y-T, Na H, Ryu H, Chung Y. Modulation of dendritic cell function by different anesthetics on tumor cytotoxicity by natural killer cells. Int J Physiol Pathophysiol Pharmacol. 2016;31(8):1606–1612.

45. Beilin B, Shavit Y, Hart J, et al. Effects of anesthesia based on large versus small doses of fentanyl on natural killer cell cytotoxicity in the periperooperative period. Anesth Analg. 1996;82(3):492–497.

46. Gessi S, Borea PA, Bencivenni S, Fazzi D, Varani K, Merighi S. The activation of μ-opioid receptor potentiates LPS-induced NF-κB promoting an inflammatory phenotype in microglia. FEBS Lett. 2016;590(17):2813–2826.

47. Johnston IN. A role for proinflammatory cytokines and fratricide in anagiesis, tolerance, and subsequent pain facilitation induced by chronic intrathecal morphine. J Neurosci. 2004;24(33):7353–7365.

48. Li J, Yang F, Wei F, Ren X. The role of toll-like receptor 4 in tumor microenvironment. Oncotarget. 2017;8(39):66656–66667.

49. Oppermann H, Matusova M, Glasow A, et al. D,L-Methadone does not improve radio- and chemotherapy in glioblastoma in vitro. Cancer Chemother Pharmacol. 2018;83(6):1017–1024.

50. Lazarczyk M, Matyja E, Lipkowski AW. A comparative study of morphine stimulation and bupivacain inhibition of human glioblastoma T98G cell proliferation in vitro. Peptides. 2010;31(8):1606–1612.

51. Heiss A, Ammer H, Eisinger DA. delta-Opioid receptor-stimulated Akt signaling in neuroblastoma x glioma (NG108-15) hybrid cells involves receptor tyrosine kinase-mediated PI3K activation. Exp Cell Res. 2009;315(12):2115–2125.

52. Forget P, Collet V, Lavand’homme P, De Kock M. Does analgesia and condition influence immunity after surgery? Effects of fentanyl, ketamine and clonidine on natural killer activity at different ages. Eur J Anaesthesiol. 2010;27(3):233–240.

53. Beilin B, Shavit Y, Hart J, et al. Effects of anesthesia based on large versus small doses of fentanyl on natural killer cell cytotoxicity in the periperooperative period. Anesth Analg. 1996;82(3):492–497.

54. Gessi S, Borea PA, Bencivenni S, Fazzi D, Varani K, Merighi S. The activation of μ-opioid receptor potentiates LPS-induced NF-κB promoting an inflammatory phenotype in microglia. FEBS Lett. 2016;590(17):2813–2826.

55. Johnston IN. A role for proinflammatory cytokines and fratricide in anagiesis, tolerance, and subsequent pain facilitation induced by chronic intrathecal morphine. J Neurosci. 2004;24(33):7353–7365.

56. Li J, Yang F, Wei F, Ren X. The role of toll-like receptor 4 in tumor microenvironment. Oncotarget. 2017;8(83):66656–66667.

57. Yao RR, Li JH, Zhang R, Chen RX, Wang YH. M2-polarized tumor-associated macrophages facilitated migration and epithelial-mesenchymal transition of HCC cells via the TLR4/STAT3 signaling pathway. World J Surg Oncol. 2018;16(19).

58. Nguyen J, Luk K, Vang D, et al. Morphine stimulates cancer progression and mast cell activation and impairs survival in transgenic mice with breast cancer. Br J Anaesth. 2014;113(suppl 1):4–13.

59. Gjorgevski M, Hannen R, Carl B, et al. Molecular profiling of the tumor microenvironment in glioblastoma patients: correlation of microglia/macrophage polarization state with metalloprotease expression profiles and survival. Biosci Rep. 2019;39(6):BSR20182361.

60. Shono T, Toflon PJ, Bruner JM, Owellali O, Lang FF. Cyclooxygenase-2 expression in human gliomas: prognostic significance and molecular correlations. Cancer Res. 2001;61(11):4375–4381.

61. Xu K, Wang L, Shu H-KS. COX-2 overexpression increases malignant potential of human glioma cells through Id1. Oncotarget. 2013;5(5):1241–1252.

62. Kang K, Zhu C, Yong S, Gao Q, Wong M. Enhanced sensitivity of celecoxib in human glioblastoma cells: induction of DNA damage leading to p53-dependent G1 cell cycle arrest and apoptosis. Mol Cancer. 2009;8(166).

63. Eberstál S, Badn W, Fritzell S, et al. Inhibition of cyclooxygenase-2 enhances immunotherapy against experimental brain tumors. Cancer Immunol Immunother. 2012;61(8):1191–1199.

64. Suzuki K, Gerechtko A, Hong Z, et al. Celecoxib enhances radiosensitivity of hypoxic glioblastoma cells through endoplasmic reticulum stress. Neuro Oncol. 2013;15(9):1186–1189.

65. Sharma V, Dixit D, Ghosh S, Sen E. COX-2 regulates the proliferation of glioma stem like cells. Neurochem Int. 2011;59(5):567–571.

66. Sareddy GR, Kesanaikuturi D, Kirti PB, Babu BP. Nonsteroidal anti-inflammatory drugs diclofenac and celecoxib attenuates Wnt/β-catenin/ Tcf signaling pathway in human glioblastoma cells. Neurochem Res. 2013;38(11):2313–2322.

67. Sareddy GR, Geewa vim K, Ramulu C, Babu BP. The nonsteroidal anti-inflammatory drug celecoxib suppresses the growth and induces apoptosis of human glioblastoma cells via the NF-κB pathway. J Neurooncol. 2012;106(1):99–109.

68. Penas-Prado M, Hess KR, Fisch MJ, et al.; MD Anderson Community Clinical Oncology Program; Brain Tumor Trials Collaborative. Randomized
phase II adjuvant factorial study of dose-dense temozolomide alone and in combination with isotretinoin, celecoxib, and/or thalidomide for glioblastoma. *Neuro Oncol.* 2015;17(2):266–273.

69. Kesari S, Schiff D, Henson JW, et al. Phase II study of temozolomide, thalidomide, and celecoxib for newly diagnosed glioblastoma in adults. *Neuro Oncol.* 2008;10(3):300–308.

70. Levin VA, Giglio P, Puduvali VK, et al. Combination chemotherapy with 13-cis-retinoic acid and celecoxib in the treatment of glioblastoma multiforme. *J Neurooncol.* 2006;78(1):85–90.

71. Grossman SA, Olson J, Batchelor T, et al.; New Approaches to Brain Tumor Therapy CNS Consortium. Effect of phenytoin on celecoxib pharmacokinetics in patients with glioblastoma. *Neuro Oncol.* 2008;10(2):190–198.

72. Oksuz E, Atalar F, Tanverdi G, Bilir A, Shahzadi A, Yazici Z. Therapeutic potential of cyclooxygenase-3 inhibitors in the management of glioblastoma. *J Neurooncol.* 2006;78(1):85–90.

73. Bernardi A, Braganhol E, Jäger E, et al. Indomethacin-loaded nanocapsules treatment reduces in vivo glioblastoma growth in a rat glioma model. *Cancer Lett.* 2009;281(1):53–63.

74. da Silveira EF, Chassot JM, Teixeira FC, et al. Ketoprofen-loaded polymeric nanocapsules selectively inhibit cancer cell growth in vitro and in preclinical model of glioblastoma multiforme. *Invest New Drugs.* 2013;31(6):1424–1435.

75. Bartels LE, Mattheolabakis G, Vaeth BM, et al. The novel agent phosphoglycerol-ibuprofen-amide (MDC-330) inhibits glioblastoma growth in mice: an effect mediated by cyclin D1. *Carcinogenesis.* 2016;37(4):420–429.

76. Wakimoto N, Wolf I, Yin D, et al. Nonsteroidal anti-inflammatory drugs suppress glioma via 15-hydroxyprostaglandin dehydrogenase. *Cancer Res.* 2008;68(17):6978–6986.

77. Najbauer J, Leidgans V, Seliger C, et al. Ibuprofen and diclofenac restrict migration and proliferation of human glioma cells by distinct molecular mechanisms. *PLoS One.* 2015;10(10).

78. Pantovic A, Bosnjak M, Arsikin K, et al. In vitro antglioma action of indomethacin is mediated via AMP-activated protein kinase/mTOR complex 1 signalling pathway. *Int J Biochem Cell Biol.* 2017;83:84–96.

79. Foulkes NS, Posadas I, Santos P, Ceña V. Acetaminophen induces human neuroblastoma cell death through NFkB activation. *PLoS One.* 2012;7(11):e50160.

80. Scheurer ME, Amirian ES, Davlin SL, Rice T, Wrensch M, Bondy ML. Effects of antihistamine and anti-inflammatory medication use on risk of specific glioma histologies. *Int J Cancer.* 2011;129(9):2290–2296.

81. Egan KM, Nabors LB, Thompson ZJ, et al. Analgesic use and the risk of primary adult brain tumor. *Eur J Epidemiol.* 2016;31(9):917–925.

82. Daugherty SE, Moore SC, Pfeiffer RM, et al. Nonsteroidal anti-inflammatory drugs and glioma in the NIH-AARP Diet and Health Study cohort. *Cancer Prev Res (Phila.)* 2011;4(12):2027–2034.

83. Kata JP, Guerra CE, Chang GJ, Gottumukkala V, Joshi GP. Non-steroidal anti-inflammatory drugs in the oncological surgical population: beneficial or harmful? A systematic review of the literature. *Br J Anaesth.* 2017;119(4):750–764.

84. Grosser T, Yu Y, Fitzgerald GA. Emotion recollected in tranquility: lessons learned from the COX-2 saga. *Annu Rev Med.* 2010;61:17–33.

85. Semenkow S, Li S, Kahlert UD, et al. An immunocompetent mouse model of human glioblastoma. *Oncotarget.* 2017;8(37):61072–61082.